AMPH Amphastar Pharmaceuticals, Inc.

15.77
-0.08  -0.44%
Previous Close 15.84
Open 15.94
Price To book 2.22
Market Cap 725.78M
Shares 46,023,000
Volume 294,592
Short Ratio 6.68
Av. Daily Volume 401,150

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 17516993
  2. 8-K - Current report 162069648
  3. 8-K - Current report 161989059
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161982735
  5. 8-K - Current report 161981545

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Albuterol DPI
Asthma
PDUFA February 19, 2017.
Naloxone Intranasal
Opioid overdose
CRL issued December 27, 2016.
Primatene Mist (epinephrine inhalation aerosol)
Asthma

Latest News

  1. Lifshitz & Miller Law Firm Announces Investigation of Ally Financial Inc., Amphastar Pharmaceuticals, Inc., Lannett Company, Inc., Live Ventures Incorporated, MiMedx Group, Inc., Seattle Genetics, Inc., Teligent, Inc., TerraVia Holdings, In
  2. 6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
  3. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Amphastar Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
  4. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amphastar Pharmaceuticals, Inc. - AMPH
  5. Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded
  6. Amphastar Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMPH) : December 29, 2016
  7. IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Amphastar Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
  8. Amphastar Stock Down on CRL for Asthma Drug in the U.S.
  9. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amphastar Pharmaceuticals, Inc. (AMPH)
  10. Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : December 28, 2016
  11. SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Amphastar Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
  12. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amphastar Pharmaceuticals, Inc. - AMPH
  13. Amphastar Slides After Receiving CRL From the FDA
  14. AMPHASTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  15. Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene® Mist
  16. Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene® Mist
  17. Do Hedge Funds Love Amphastar Pharmaceuticals Inc (AMPH)?
  18. Amphastar Pharmaceuticals to Present at the 2016 Piper Jaffray Healthcare Conference
  19. AMPHASTAR PHARMACEUTICALS, INC. Financials

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 17516993
  2. 8-K - Current report 162069648
  3. 8-K - Current report 161989059
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161982735
  5. 8-K - Current report 161981545
  6. UPLOAD [Cover] - SEC-generated letter
  7. CORRESP [Cover] - Correspondence
  8. UPLOAD [Cover] - SEC-generated letter
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161815939
  10. 8-K - Current report 161814460